natgillin/translations-raw huggingface dataset:
Glycopyrronium virker ved at blokere den bronkokonstiktive virkning af acetylcholin på de glatte muskelceller i luftvejene, og derved dilatere dem. Glycopyrroniumbromid er en muskarinreceptor med en høj affinitet, og der er blevet påvist en selektivitet over for humane M3-receptorer, der var 4-gange større end for humane M2-receptorer.
Glycopyrronium bromide is a high affinity muscarinic receptor antagonist with a greater than 4-fold selectivity for the human M3 receptors over the human M2 receptor as it has been demonstrated.
• uregelmæssigt hjerteslag
• irregular heart beat
Før trykbeholderne med 60, 120 eller 180 pust primes, skal der stå henholdsvis.
Before priming the 60, 120 or 180 actuation pressurised containers, the counter/indicator should read 61, 121 or 180, respectively.
Sørg for ikke at tabe inhalatoren, da det kan få dosistælleren til at tælle ned.
Take care not to drop the inhaler as this may cause the counter to count down.
Priming af inhalatoren
Priming the inhaler
Patienterne skal fjerne beskyttelseslåget fra mundstykket og kontrollere, at mundstykket er rent og uden støv og snavs eller andre fremmedlegemer.
IMPORTANT: steps 2 to 5 should not be performed too quickly: Patients should remove the protective cap from the mouthpiece and check that the mouthpiece is clean and free from dust and dirt or any other foreign objects.
Trykbeholder med 60 pust:
60 actuation pressurised container:
Sammenlignet med en fastdosiskombination af indacaterol og glycopyrronium nedsatte Riarify hyppigheden af moderate/svære eksacerbationer i løbet af 52 uger med 15 % (hyppighed: 0,50 versus 0,59 hændelser pr. patient/år, p = 0,043).
Compared with a fixed combination of indacaterol and glycopyrronium, Riarify reduced the rate of moderate/severe exacerbations over 52 weeks by 15% (rate: 0.50 versus 0.59 events per patient/year; p = 0.043).
Trombocytopeni1
Thrombocytopenia1
Desuden bør en langvarig administration af Riarify sammen med andre lægemidler, der indeholder antikolinergika, ikke anvendes, på grund af den antikolinerge virkning af glycopyrronium (se pkt.
Additionally, due to the anticholinergic effect of glycopyrronium, the long-term co-administration of Riarify with other anticholinergic-containing medicinal products is not recommended (see section 4.5).
• åndenød eller stakåndethed
• feeling breathless or short of breath
Sammenlignet med en fast kombination af beclometasondipropionat og formoterol forbedrede Riarify FEV1 2-timer efter dosering med 117 ml efter 26 ugers behandling, og med 103 ml efter 52 ugers behandling (p < 0,001).
Compared with a fixed combination of beclometasone dipropionate and formoterol, Riarify significantly improved 2-hour post dose FEV1 by 117 mL after 26 weeks of treatment and by 103 mL after 52 weeks of treatment (p < 0.001).
Efter priming skal der stå 60, 120 eller 180 på dosistælleren/indikatoren.
After priming, the counter/indicator should read 60, 120 or 180.
• svampeinfektioner i skeden
• fungal infections of the chest
Beclometason er mindre afhængig af CYP3A-metabolisering end visse andre kortikosteroider, og generelt er interaktion ikke sandsynlig.
Beclometasone is less dependent on CYP3A metabolism than some other corticosteroids, and in general interactions are unlikely; however, the possibility of systemic effects with concomitant use of strong CYP3A inhibitors (e.g. ritonavir, cobicistat) cannot be excluded, and therefore caution and appropriate monitoring is advised with the use of such medicinal products.
Indlægsseddel: Information til brugeren Riarify 87 mikrogram/5 mikrogram/9 mikrogram inhalationsspray, opløsning beclometasondipropionat/formoterolfumaratdihydrat/glycopyrronium (beclometasoni dipropionas/formoteroli fumaras dihydricus/glycopyrronium)
Package leaflet: Information for the user Riarify 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium
Sammenlignet med en fastdosiskombination af beclometasondipropionat og formoterol nedsatte Riarify hyppigheden af moderate/svære eksacerbationer i løbet af 52 uger med 23 % (hyppighed: 0,41 versus 0,53 hændelser pr. patient/år, p = 0,005).
Compared with a fixed combination of beclometasone dipropionate and formoterol, Riarify reduced the rate of moderate/severe exacerbations over 52 weeks by 23% (rate: 0.41 versus 0.53 events per patient/year; p = 0.005).
Den daglige dosis af Riarify svarer til en medium dosis af inhaleret kortikosteroid.
The daily dose of Riarify corresponds to a medium dose of inhaled corticosteroid; furthermore, these effects are much less likely to occur than with oral corticosteroids.
Riarify 87/5/9 mikrogram inhalationsspray beclometasoni dipropionas/formoteroli fumaras dihydricus/glycopyrronium Til inhalation
Riarify 87/5/9 micrograms pressurised inhalation beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium Inhalation use
Sammenlignet med en fast kombination af beclometasondipropionat og formoterol forbedrede Riarify FEV1 før dosering med 81 ml efter 26 ugers behandling og med 63 ml efter 52 ugers behandling.
Compared with a fixed combination of beclometasone dipropionate and formoterol, Riarify improved pre-dose FEV1 by 81 mL after 26 weeks of treatment and by 63 mL after 52 weeks of treatment.
Sammenlignet med tiotropium nedsatte Riarify hyppigheden af moderate/svære eksacerbationer i løbet af 52 uger med 20 % (hyppighed: 0,46 versus 0,57 hændelser pr. patient/år, p = 0,003).
Compared with tiotropium, Riarify reduced the rate of moderate/severe exacerbations over 52 weeks by 20% (rate: 0.46 versus 0.57 events per patient/year; p = 0.003).
Patienter med svært nedsat leverfunktion
Patients with severe renal impairment
Riarify 87/5/9 mikrogram inhalationsspray, opløsning beclometasoni dipropionas/formoteroli fumaras dihydricus/glycopyrronium
Riarify 87/5/9 micrograms pressurised inhalation, solution beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium
For trykbeholderen med 180 pust vil der blive frigivet en dosis af opløsningen, hver gang patienten trykker på trykbeholderen, og dosistælleren roterer lidt.
For the 180 actuation pressurised container, each time the patient presses the pressurised container a puff of the solution is released and the counter rotates by a small amount; the number of puffs remaining is displayed in intervals of 20.
Hjælpestoffer: vandfri ethanol, saltsyre, drivmiddel: norfluran.
Excipients: anhydrous ethanol, hydrochloric acid; propellant: norflurane.
Forud for absorptionen finder der en omfattende konvertering til beclometason-17-monopropionat sted via esteraseenzymerne, der findes i de fleste væv.
Inhaled beclometasone dipropionate is rapidly absorbed through the lungs; prior to absorption there is extensive conversion to beclometasone 17-monopropionate via esterase enzymes that are found in most tissues.
Den gennemsnitlige halveringstid for elimination af glycopyrronium hos raske frivillige var ca. 6 timer efter i.v.-injektion, mens det varierede fra 5 til 12 timer ved steady state efter inhalation hos KOL-patienter.
The mean elimination half-life of glycopyrronium in healthy volunteers was approximately 6 hours after i.v.
Angioødem1
Angioedema1
Hold inhalatoren opret med mundstykket forneden, og placer mundstykket mellem tænderne uden at bide i det.
Patients should hold the inhaler vertically with its body upwards and place the mouthpiece between their teeth without biting.
Sygdomsforværring
Deterioration of disease
Farveløs til gullig, flydende opløsning.
Colourless to yellowish liquid solution.
• nyrebetændelse.
• inflammation of the kidneys.
• rysten
• tiredness
Hver leverede dosis indeholder 87 mikrogram beclometasondipropionat, 5 mikrogram formoterolfumaratdihydrat og 9 mikrogram glycopyrronium.
Each delivered dose contains 87 micrograms of beclometasone dipropionate, 5 micrograms of formoterol fumarate dihydrate and 9 micrograms of glycopyrronium.
Sådan skal du bruge Riarify
How to use Riarify
Patienter med svært nedsat nyrefunktion:
Patients with severe hepatic impairment
Nedsat knoglemineralsk densitet1
Bone density decreased1
• ondt i halsen
• irritation of the throat
Hver afmålte dosis (dosis, der forlader ventilen) indeholder 100 mikrogram beclometasondipropionat, 6 mikrogram formoterolfumaratdihydrat og 10 mikrogram glycopyrronium.
Each metered dose (the dose leaving the valve) contains 100 micrograms of beclometasone dipropionate, 6 micrograms of formoterol fumarate dihydrate and 10 micrograms of glycopyrronium.
moderate eksacerbationer) med 32 % (hyppighed: 0,067 versus 0,098 hændelser pr. patient/år, p = 0,017).
Compared with tiotropium, Riarify also reduced the rate of severe exacerbations (i.e. excluding moderate exacerbations) by 32% (rate: 0.067 versus 0.098 events per patient/year; p = 0.017).
Hver leveret dosis (dosis, der forlader mundstykket) indeholder 87 mikrogram beclometasondipropionat (beclometasoni dipropionas), 5 mikrogram formoterolfumaratdihydrat (formoteroli fumaras dihydricus) og 9 mikrogram glycopyrronium (glycopyrronium) (som 11 mikrogram glycopyrroniumbromid).
Each delivered dose (the dose leaving the mouthpiece) contains 87 micrograms of beclometasone dipropionate, 5 micrograms of formoterol fumarate dihydrate and 9 micrograms of glycopyrronium (as 11 micrograms glycopyrronium bromide).
• ørebetændelse
• inflammation of the ear
Af hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet eller skraldespanden.
Medicines should not be disposed of via waste water or household waste.
Desuden blev virkningerne sammenlignet med en ekstemporær trippelkombination, der bestod af en fast kombination af to inhalationer af beclometasondipropionat og formoterol 100/6 mikrogram to gange dagligt plus tiotropium 18 mikrogram inhalationspulver, hård kapsel, en inhalation én gang dagligt (2.691 randomiserede patienter).
Study TRINITY compared Riarify with tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily; in addition, effects were compared with an extemporary triple combination made of a fixed combination of beclometasone dipropionate and formoterol 100/6 micrograms two inhalations twice daily plus tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily (2,691 randomised patients).
Efter udlevering kan inhalatoren opbevares ved temperaturer op til 25 °C i maksimalt 4 måneder.
After dispensing, the medicinal product may be stored for a maximum of 4 months at a temperature up to 25°C.
• hvis du skal bedøves.
• if you are due to have an anaesthetic.
• hududslæt, nældefeber, hudkløe
• skin rash, hives, skin itching
Ethanol, vandfrit Saltsyre
Ethanol anhydrous Hydrochloric acid Norflurane (propellant)
Nyrer og urinveje Dysuri, urinretention, nefritis1
Dysuria, urinary retention, nephritis1
Hver afmålte dosis (der forlader ventilen) indeholder 100 mikrogram beclometasondipropionat, 6 mikrogram formoterolfumaratdihydrat og 10 mikrogram glycopyrronium (som 12,5 mg glycopyrroniumbromid).
Each metered dose (the dose leaving the valve) contains 100 micrograms of beclometasone dipropionate, 6 micrograms of formoterol fumarate dihydrate and 10 micrograms of glycopyrronium (as 12.5 micrograms of glycopyrronium bromide).
Hver afmålte dosis (dosis, der forlader ventilen) indeholder 100 mikrogram beclometasondipropionat (beclometasoni dipropionas), 6 mikrogram formoterolfumaratdihydrat (formoteroli fumaras dihydricus) og 10 mikrogram glycopyrronium (glycopyrronium) (som 12,5 mikrogram glycopyrroniumbromid).
Each metered dose (the dose leaving the valve) contains 100 micrograms of beclometasone dipropionate, 6 micrograms of formoterol fumarate dihydrate and 10 micrograms of glycopyrronium (as 12.5 micrograms glycopyrronium bromide).
Otosalpingitis1
Restlessness1
Træthed1
Fatigue1
• betændelse og rødme i svælget
• inflammation and redness of the pharynx
• træthed
• numbness
Denne forskel til fordel for Galliprant var statistisk signifikant (p-værdi = 0,0008).
This difference in favour of Galliprant was statistically significant (p-value= 0.0008).
Et klinisk respons på behandling ses sædvanligvis inden for 7 dage.
A clinical response to treatment is usually seen within 7 days.
26 Rue de la Chapelle 68330 Huningue Frankrig
26 Rue de la Chapelle 68330 Huningue France
Der observeres ingen kønsrelaterede forskelle i absorption.
No gender related differences in absorption are observed.
DATO FOR FØRSTE TILLADELSE/FORNYELSE AF TILLADELSEN Dato for første markedsføringstilladelse: 09/01/2018
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 09/01/2018
Halveringstiden for elimination af grapiprant er ca. 4,6 til 5,67 timer.
The elimination half-life of grapiprant is approximately 4.6 to 5.67 hours.
Følgende antal af tabletter skal gives en gang dagligt:
The following number of tablets should be given once daily:
Varigheden af behandlingen vil afhænge af responset på behandling.
Duration of treatment will depend on the response observed to treatment.
Ca. 70-80 % af den administrerede dosis udskilles i løbet af 48-72 timer med hovedparten af dosen udskilt uændret.
Approximately 70-80% of the administered dose is excreted within 48-72 h with the majority of the dose excreted unchanged.
Sikkerheden af veterinærlægemidlet er ikke blevet fastlagt hos hunde, der er under 9 måneder gamle, og hos hunde, der vejer mindre end 3,6 kg.
The safety of the veterinary medicinal product has not been established in dogs under 9 months of age and in dogs weighing less than 3.6 kg.
SÆRLIGE OPBEVARINGSBETINGELSER Må ikke opbevares over 30 °C.
SPECIAL STORAGE CONDITIONS Do not store above 30 °C.
Administrér dette veterinærlægemiddel på en tom mave (f.eks. om morgenen) og mindst én time før det næste måltid én gang dagligt med en måldosis på 2 mg pr. kg legemsvægt.
Administer this veterinary medicinal product on an empty stomach (e.g. in the morning) and at least one hour before the next meal, once daily at a target dose of 2 mg per kg body weight.
Veterinærlægemidlet findes i følgende pakningsstørrrelser:
The veterinary medicinal product is available in the following pack sizes:
Grapiprant akkumuleres ikke i hunden efter gentagen administration.
Grapiprant does not accumulate in the dog after repeated administration.
Vask hænder efter håndtering af veterinærlægemidlet.
Wash hands after handling of the veterinary medicinal product.
Den farmakologiske aktivitet af metabolitterne er ikke kendt.
The pharmacological activity of the metabolites is not known.
I tilfælde af en overdosis skal der iværksættes symptomatisk behandling.
In case of overdose, symptomatic treatment should be initiated.
Grapiprant er et methylbenzensulfonamid.
Grapiprant is a methylbenzenesulfonamide.
Udskillelse via afføring udgjorde ca. 65 % af dosen, hvorimod ca. 20 % af dosen blev udskilt via urin.
Faecal excretion accounted for roughly 65% of the dose whereas approximately 20% of the dose was excreted through urine.
Lægemiddelforenelighed bør overvåges hos dyr, der har brug for supplerende behandling.
Drug compatibility should be monitored in animals requiring adjunctive therapy.
Hvis der ikke ses nogen klinisk forbedring efter 14 dage, bør behandling med Galliprant afbrydes, og andre behandlingsmuligheder bør undersøges i samråd med dyrlægen.
If no clinical improvement is apparent after 14 days, treatment with Galliprant should be discontinued and different treatment options should be explored in consultation with the veterinarian.
Da feltstudier var begrænset til 28 dage, bør langtidsbehandling overvejes nøje, og dyrlægen bør foretage regelmæssig overvågning.
As field studies were limited to 28 days, longer-term treatment should be considered carefully and regular monitoring undertaken by the veterinarian.
EU/2/17/221/001 (20 mg, 7 tabletter, 20 ml beholder) EU/2/17/221/002 (20 mg, 30 tabletter, 20 ml beholder) EU/2/17/221/003 (60 mg, 7 tabletter, 20 ml beholder) EU/2/17/221/004 (60 mg, 30 tabletter, 35 ml beholder) EU/2/17/221/005 (100 mg, 7 tabletter, 35 ml beholder) EU/2/17/221/006 (100 mg, 30 tabletter, 60 ml beholder)
EU/2/17/221/001 (20 mg, 7 tablets, 20 ml bottle) EU/2/17/221/002 (20 mg, 30 tablets, 20 ml bottle) EU/2/17/221/003 (60 mg, 7 tablets, 20 ml bottle) EU/2/17/221/004 (60 mg, 30 tablets, 35 ml bottle) EU/2/17/221/005 (100 mg, 7 tablets, 35 ml bottle) EU/2/17/221/006 (100 mg, 30 tablets, 60 ml bottle)
Maksimale koncentrationer af grapiprant observeres i serum i løbet af én time efter dosering i fastende tilstand.
Maximum grapiprant concentrations are observed in serum within one hour of dosing in the fasted state.
Tabletten kan deles i to lige store dele.
The tablet can be divided into equal halves.
Yderligere information om dette lægemiddel er tilgængelig på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Der er observeret lette fald i serumalbumin og total protein, hyppigst inden for referenceområdet, hos hunde behandlet med grapiprant, men de var ikke forbundet med klinisk signifikante observationer eller hændelser.
Mild decreases in serum albumin and total protein, most often within the reference range, have been observed in dogs treated with grapiprant but were not associated with any clinically significant observations or events.
Størstedelen af de kliniske tilfælde, der blev vurderet i de kliniske feltstudier, led af let til moderat osteoarthritis baseret på en dyrlægevurdering.
The majority of clinical cases assessed in the clinical field studies suffered from mild to moderate osteoarthritis based on the veterinary assessment.
ANGIVELSE AF DE(T) AKTIVE STOF(FER) OG ANDRE INDHOLDSSTOFFER Én tablet indeholder:
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS One tablet contains:
Anvendelse af grapiprant sammen med andre antiinflammatoriske midler er ikke blevet undersøgt og bør undgås.
The concurrent use of grapiprant with other anti-inflammatory agents has not been studied and should be avoided.
Hyppigheden af bivirkninger er defineret som: - Meget almindelig (flere end 1 ud af 10 behandlede dyr, der viser bivirkninger i løbet af en behandling) - Almindelig (flere end 1, men færre end 10 dyr ud af 100 behandlede dyr) - Ikke almindelig (flere end 1, men færre end 10 dyr ud af 1.000 behandlede dyr) - Sjælden (flere end 1, men færre end 10 dyr ud af 10.000 behandlede dyr) - Meget sjælden (færre end 1 dyr ud af 10.000 behandlede dyr, herunder isolerede rapporter).
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
For at opnå et underbygget respons på behandling skal veterinærlægemidlet kun anvendes ved lette og moderate tilfælde af osteoarthritis.
To achieve a substantiated response to treatment, use the veterinary medicinal product only in mild and moderate cases of osteoarthritis.
Fire metabolitter er identificeret, og metaboliseringsvejene omfatter N-deaminering til frembringelse af den primære metabolit i afføring (7,2 %) og urin (3,4 %).
Four metabolites are identified and the metabolic pathways include Ndeamination to form the major metabolite in faeces (7.2%) and urine (3.4%).
Den gennemsnitlige procent af ubundet grapiprant var henholdsvis 4,35 % og 5,01 % ved en koncentration af grapiprant på 200 ng/ml og 1000 ng/ml.
The mean percentage of unbound grapiprant was 4.35% and 5.01% at a grapiprant concentration of 200 ng/ml and 1000 ng/ml.
Almindeligt anvendte proteinbundne veterinærlægemidler omfatter hjerterelaterede, antikonvulsive og adfærdsregulerende lægemidler.
Commonly used protein-bound veterinary medicinal products include cardiac, anticonvulsant and behavioural medications.
Den behandlingsfri periode skal tage højde for de farmakokinetiske egenskaber ved de tidligere anvendte præparater.
The treatment-free period should take into account the pharmacokinetic properties of the products used previously.
Grapiprant bindes primært til serumproteiner.
Grapiprant is primarily bound to serum proteins.
Indtagelse af tabletten sammen med mad reducerer den orale biotilgængelighed, dvs den orale biotilgængelighed af grapiprant var 89 %, når den blev taget i fastende tilstand, mens den var 33 %, når den blev taget sammen med mad, med gennemsnitlige Cmaxog AUC-grapiprantværdier, der var reduceret med henholdsvis en faktor 4 og en faktor 2.
Intake of the tablet with food reduces the oral bioavailability, i.e. the oral bioavailability of grapiprant when taken in the fasted state was 89% and when taken with food it was 33%, with mean Cmax and AUC grapiprant values reduced 4-fold and 2-fold, respectively.
Efter en enkelt oral dosis på 2 mg grapiprant/kg i fastende tilstand blev der nået Cmax- og AUC-værdier på 1,21 µg/ml og 2,71 µg.h/ml.
After a single oral dose of 2 mg grapiprant/kg, Cma x and AUC values of 1.21 µg/ml and 2.71 µg.h/ml were reached in the fasted state.
Hvis der opstår tegn på overfølsomhed over for sulfonamid, skal behandlingen afbrydes.
If signs of sulphonamide hypersensitivity occur, treatment should be discontinued.
Samtidig anvendelse af proteinbundne veterinærlægemidler med grapiprant er ikke blevet undersøgt.
The concomitant use of protein-bound veterinary medicinal products with grapiprant has not been studied.
For at undgå utilsigtet indtagelse skal tabletterne opbevares utilgængeligt for dyr.
In order to avoid any accidental ingestion, store tablets out of reach of animals.
Eventuelle resterende hele og halve tabletter skal kasseres 3 måneder efter første åbning.
Any remaining whole and half tablets should be discarded after 3 months following first opening.
Hos hunde er grapiprant et væsentligt ekskretionsprodukt i galde, afføring og urin.
In dogs, grapiprant is a major excretion product in bile, faeces and urine.
DATO FOR SENESTE GODKENDELSE AF INDLÆGSSEDLEN Yderligere information om dette veterinærlægemiddel er tilgængelig på Det Europæiske Lægemiddelagenturs hjemmeside (http://www.ema.europa.eu).
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Én hvid HDPE-tabletbeholder med børnesikret låg, der indeholder 7 eller 30 tabletter (20 mg, 60 mg eller 100 mg tabletter).
One white HDPE bottle with a child-resistant cap containing 7 or 30 tablets (20 mg, 60 mg or 100 mg tablets).
I de to kliniske feltstudier var de samlede succesrater baseret på CBPI (Canine Brief Pain Inventory, som blev udfyldt af ejeren) 28 dage efter start på behandlingen 51,3 % (120/235) for Galliprant og 35,5 % (82/231) for placebo-gruppen.
From the two clinical field studies, the overall success rates based on CBPI (Canine Brief Pain Inventory, as completed by the owner) at 28 days after the start of the treatment, were 51.3% (120/235) for Galliprant and 35.5% (82/231) for the placebo group.
Cellulose, mikrokrystallinsk Magnesiumstearat Silica, kolloid vandfri
Cellulose, microcrystalline Magnesium stearate Silica, colloidal anhydrous
Farmakoterapeutisk gruppe: Andre antiinflammatoriske midler og antireumatika, non-steroider ATCvet-kode:
Pharmacotherapeutic group: Other anti-inflammatory and antirheumatic agents, non-steroids ATCvet code:
Eventuelle halve tabletter skal opbevares i beholderen.
Any half tablets should be stored in the bottle.
Det er uvist, om hunde med overfølsomhed over for sulfonamider vil udvise overfølsomhed over for grapiprant.
It is not known whether dogs with a history of hypersensitivity to sulphonamides will exhibit hypersensitivity to grapiprant.
Grapiprant er en selektiv antagonist for EP4-receptoren, en nøgle-prostaglandin E2-receptor, der overvejende medierer prostaglandin E2‐fremkaldt nociception.
Grapiprant is a selective antagonist of the EP4 receptor, a key prostaglandin E2 receptor that predominantly mediates prostaglandin E2‐elicited nociception.